Growth rate-corrected (GR) dose-response metrics across a panel of 71 breast cancer cell lines treated with a library of small molecule and antibody perturbagens. Dataset 1 of 4: Relative cell counts and normalized growth rate inhibition values across technical replicates. - Dataset (ID:20268)
Download: Excel (XLSX), Comma-separated (CSV)
| Cell | Clinical Subtype | Transcriptional Subtype | Small Molecule | Antibody | Perturbagen Target | Perturbagen Class | Perturbagen Concentration | Perturbagen Conc Unit | Biological Replicate ID | Relative Cell Count | Normalized Growth Rate Inhibition Value | Nominal Division Rate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| HCC2185 | TNBC | Luminal | Selumetinib | MEK | MAPK | 2 | uM | 12192.155 | 0.8832 | 0.6930 | 0.7451 | |
| HCC2185 | TNBC | Luminal | Selumetinib | MEK | MAPK | 10 | uM | 12192.155 | 1.0636 | 1.1725 | 0.7451 | |
| HCC2185 | TNBC | Luminal | Selumetinib | MEK | MAPK | 50 | uM | 12192.155 | 0.9380 | 0.8352 | 0.7451 | |
| HCC3153 | TNBC | Basal A | Selumetinib | MEK | MAPK | 0.000128 | uM | 10937.155 | 0.9856 | 0.9780 | 1.3142 | |
| HCC3153 | TNBC | Basal A | Selumetinib | MEK | MAPK | 0.00064 | uM | 10937.155 | 0.9116 | 0.8640 | 1.3142 | |
| HCC3153 | TNBC | Basal A | Selumetinib | MEK | MAPK | 0.0032 | uM | 10937.155 | 0.9614 | 0.9410 | 1.3142 | |
| HCC3153 | TNBC | Basal A | Selumetinib | MEK | MAPK | 0.016 | uM | 10937.155 | 0.9807 | 0.9706 | 1.3142 | |
| HCC3153 | TNBC | Basal A | Selumetinib | MEK | MAPK | 0.08 | uM | 10937.155 | 0.8867 | 0.8252 | 1.3142 | |
| HCC3153 | TNBC | Basal A | Selumetinib | MEK | MAPK | 0.4 | uM | 10937.155 | 0.9237 | 0.8828 | 1.3142 | |
| HCC3153 | TNBC | Basal A | Selumetinib | MEK | MAPK | 2 | uM | 10937.155 | 0.8202 | 0.7200 | 1.3142 | |
| HCC3153 | TNBC | Basal A | Selumetinib | MEK | MAPK | 10 | uM | 10937.155 | 0.9415 | 0.9103 | 1.3142 | |
| HCC3153 | TNBC | Basal A | Selumetinib | MEK | MAPK | 50 | uM | 10937.155 | 0.8488 | 0.7654 | 1.3142 | |
| HCC38 | TNBC | Basal B | Selumetinib | MEK | MAPK | 0.000128 | uM | 11850.155 | 0.9652 | 0.9678 | 2.1810 | |
| HCC38 | TNBC | Basal B | Selumetinib | MEK | MAPK | 0.00064 | uM | 11850.155 | 0.8845 | 0.8906 | 2.1810 | |
| HCC38 | TNBC | Basal B | Selumetinib | MEK | MAPK | 0.0032 | uM | 11850.155 | 0.9251 | 0.9299 | 2.1810 | |
| HCC38 | TNBC | Basal B | Selumetinib | MEK | MAPK | 0.016 | uM | 11850.155 | 1.0080 | 1.0073 | 2.1810 | |
| HCC38 | TNBC | Basal B | Selumetinib | MEK | MAPK | 0.08 | uM | 11850.155 | 0.9354 | 0.9396 | 2.1810 | |
| HCC38 | TNBC | Basal B | Selumetinib | MEK | MAPK | 0.4 | uM | 11850.155 | 0.9181 | 0.9232 | 2.1810 | |
| HCC38 | TNBC | Basal B | Selumetinib | MEK | MAPK | 2 | uM | 11850.155 | 0.8362 | 0.8425 | 2.1810 | |
| HCC38 | TNBC | Basal B | Selumetinib | MEK | MAPK | 10 | uM | 11850.155 | 0.9525 | 0.9559 | 2.1810 | |
| HCC38 | TNBC | Basal B | Selumetinib | MEK | MAPK | 50 | uM | 11850.155 | 0.9228 | 0.9277 | 2.1810 | |
| HCC70 | TNBC | Basal A | Selumetinib | MEK | MAPK | 0.000128 | uM | 10873.155 | 0.9984 | 0.9975 | 1.2787 | |
| HCC70 | TNBC | Basal A | Selumetinib | MEK | MAPK | 0.00064 | uM | 10873.155 | 1.0334 | 1.0521 | 1.2787 | |
| HCC70 | TNBC | Basal A | Selumetinib | MEK | MAPK | 0.0032 | uM | 10873.155 | 0.9663 | 0.9471 | 1.2787 | |
| HCC70 | TNBC | Basal A | Selumetinib | MEK | MAPK | 0.016 | uM | 10873.155 | 0.8148 | 0.7040 | 1.2787 |